Related Experiment Video
Updated: Aug 8, 2026
12:21
The Mouse Round-window Approach for Ototoxic Agent Delivery: A Rapid and Reliable Technique for Inducing Cochlear Cell Degeneration
Published on: November 26, 2015
[Hearing loss caused by high dose carboplatin therapy]
J Lautermann1, M Adamczyk, W J ten Cate
1Universitäts-Hals-Nasen-Ohrenklinik Essen.
Laryngo- Rhino- Otologie
|April 29, 1998
Summary
High-dose carboplatin, used after cisplatin chemotherapy for testicular cancer, can cause significant hearing loss. This ototoxicity affects mid and high frequencies, impacting patients who have already undergone chemotherapy.
Area of Science:
- Oncology
- Ototoxicology
- Pharmacology
Context:
- Carboplatin is generally considered less ototoxic than cisplatin.
- Testicular cancer recurrence often necessitates salvage chemotherapy regimens.
- Previous cisplatin treatment may alter susceptibility to carboplatin ototoxicity.
Purpose:
- To report cases of hearing loss following high-dose carboplatin salvage therapy in testicular cancer patients.
- To characterize the audiometric profile of carboplatin-induced hearing loss in this context.
- To investigate the potential for otoacoustic emission changes post-carboplatin treatment.
Summary:
- Three patients with recurrent testicular cancer received high-dose carboplatin after prior cisplatin chemotherapy.
- Audiometry revealed significant hearing loss, particularly in mid-to-high frequencies (up to 55 dB at 8 kHz).
- Transient-evoked otoacoustic emissions were absent in two patients, indicating cochlear dysfunction.
Impact:
- Salvage high-dose carboplatin therapy can induce ototoxicity, challenging its non-ototoxic classification in certain clinical scenarios.
- Hearing loss may be more pronounced in patients with prior platinum-based chemotherapy exposure.
- Findings highlight the need for audiological monitoring in patients receiving high-dose carboplatin, especially after cisplatin.
